Pacira Biosciences Inc. (PCRX)

43.20
NASDAQ : Health Technology
Prev Close 43.56
Day Low/High 42.93 / 43.91
52 Wk Low/High 30.00 / 55.00
Avg Volume 555.10K
Exchange NASDAQ
Shares Outstanding 41.30M
Market Cap 1.80B
P/E Ratio 242.00
Div & Yield N.A. (N.A)
Pacira Pharmaceuticals, Inc. To Host Analyst & Investor Day On Jan. 22 In New York

Pacira Pharmaceuticals, Inc. To Host Analyst & Investor Day On Jan. 22 In New York

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it has scheduled an Analyst & Investor Day on Thursday, Jan.

Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue Of $61.8 Million And Estimated Full-Year Total Revenue Of $197.7 Million

Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue Of $61.8 Million And Estimated Full-Year Total Revenue Of $197.7 Million

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided its unaudited EXPAREL® and total revenue estimates for the fourth quarter and full-year 2014.

Pacira Pharmaceuticals Inc. Announces Changes To EXPAREL® Label

Pacira Pharmaceuticals Inc. Announces Changes To EXPAREL® Label

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the U.

PCRX: Insiders vs. Shorts

PCRX: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 11/14/2014 settlement date, and Pacira Pharmaceuticals Inc. is one of the most shorted stocks of the Russell 3000, based on 6.79 "days to cover" versus the median component at 5.85.

Pacira Pharmaceuticals, Inc. To Present At The 26th Annual Piper Jaffray Healthcare Conference

Pacira Pharmaceuticals, Inc. To Present At The 26th Annual Piper Jaffray Healthcare Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 26 th Annual Piper Jaffray...

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Pacira Pharmaceuticals, Inc. To Contact Brower Piven Before The December 2, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Pacira Pharmaceuticals, Inc. To Contact Brower Piven Before The December 2, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...

Pacira Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Pacira Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a class action lawsuit...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against Pacira Pharmaceuticals, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 2, 2014

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against Pacira Pharmaceuticals, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 2, 2014

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc. To Present At The Jefferies 2014 Global London Healthcare Conference

Pacira Pharmaceuticals, Inc. To Present At The Jefferies 2014 Global London Healthcare Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2014 Global ...

Pacira Pharmaceuticals Inc. Announces New Data On The Use Of EXPAREL To Treat Postsurgical Pain Following Total Knee Arthroplasty

Pacira Pharmaceuticals Inc. Announces New Data On The Use Of EXPAREL To Treat Postsurgical Pain Following Total Knee Arthroplasty

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study designed to evaluate the difference in postsurgical pain and opioid consumption between patients ...

Today's Dead Cat Bounce Stock: Pacira Pharmaceuticals (PCRX)

Today's Dead Cat Bounce Stock: Pacira Pharmaceuticals (PCRX)

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Today's Weak On High Volume Stock: Pacira Pharmaceuticals (PCRX)

Today's Weak On High Volume Stock: Pacira Pharmaceuticals (PCRX)

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a weak on high relative volume candidate

Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue Of $50.2 Million And Third Quarter 2014 Results

Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue Of $50.2 Million And Third Quarter 2014 Results

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced...

New Study Correlates Use Of EXPAREL For Postsurgical Pain Management With Significant Reductions In Opioid Related Adverse Events

New Study Correlates Use Of EXPAREL For Postsurgical Pain Management With Significant Reductions In Opioid Related Adverse Events

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study that reinforce the positive impact of an EXPAREL-based pain management regimen on reducing ...

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Pacira Pharmaceuticals, Inc. To Contact Brower Piven Before The December 2, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Pacira Pharmaceuticals, Inc. To Contact Brower Piven Before The December 2, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...

Pacira Pharmaceuticals Announces Timing For Third Quarter 2014 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals Announces Timing For Third Quarter 2014 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s third quarter ended September 30, 2014, will be released before the market opens on Thursday, October 30, 2014.

Pacira Pharmaceuticals, Inc. Announces Additional Data Supporting Safety Of EXPAREL® In Peripheral Nerve Block

Pacira Pharmaceuticals, Inc. Announces Additional Data Supporting Safety Of EXPAREL® In Peripheral Nerve Block

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced data demonstrating that EXPAREL ® (bupivacaine liposome injectable suspension) used in peripheral nerve blocks has comparable safety to placebo...

'Mad Money' Lightning Round: Buy, Buy, Buy Buffalo Wild Wings

'Mad Money' Lightning Round: Buy, Buy, Buy Buffalo Wild Wings

Cramer still sees value in Hertz, thinks Windstream is played out and would buy into AvalonBay Communities.

Jim Cramer's 'Mad Money' Recap: Relief Rally or the Real Deal?

Jim Cramer's 'Mad Money' Recap: Relief Rally or the Real Deal?

Fund managers have been waking up, realizing the facts have changed and the earnings estimates are just too high, Cramer says.

Roy Jacobs & Associates Announces Investigation Into Possible Wrongdoing At Pacira Pharmaceuticals, Inc. (PCRX)

Roy Jacobs & Associates Announces Investigation Into Possible Wrongdoing At Pacira Pharmaceuticals, Inc. (PCRX)

Roy Jacobs & Associates a law firm representing investors nationwide, is investigating potential claims on behalf of shareholders of Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals (PCRX) Showing Signs Of A Dead Cat Bounce Today

Pacira Pharmaceuticals (PCRX) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Pacira Pharmaceuticals (PCRX) Moving On Heavy Pre-Market Trading

Pacira Pharmaceuticals (PCRX) Moving On Heavy Pre-Market Trading

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a pre-market mover with heavy volume candidate

Pacira Pharmaceuticals, Inc. Announces Receipt Of FDA Warning Letter

Pacira Pharmaceuticals, Inc. Announces Receipt Of FDA Warning Letter

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the receipt of a Warning Letter ( attached for reference) from the U.

New Lifetime High Reached By Pacira Pharmaceuticals (PCRX)

New Lifetime High Reached By Pacira Pharmaceuticals (PCRX)

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a new lifetime high candidate

New Lifetime High Today: Pacira Pharmaceuticals (PCRX)

New Lifetime High Today: Pacira Pharmaceuticals (PCRX)

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a new lifetime high candidate

Pacira Pharmaceuticals, Inc. To Present At The Wedbush 2014 Life Sciences Management Access Conference

Pacira Pharmaceuticals, Inc. To Present At The Wedbush 2014 Life Sciences Management Access Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Wedbush 2014 Life Sciences...

Fitz Bits: Buying Opportunity This Week

Fitz Bits: Buying Opportunity This Week

After moves like last week, buyers tend to nibble.

Pacira Pharmaceuticals (PCRX) Hits New Lifetime High

Pacira Pharmaceuticals (PCRX) Hits New Lifetime High

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a new lifetime high candidate

TheStreet Quant Rating: C (Hold)